The U.K. drug regulator on Wednesday approved Amgen’s (NASDAQ:AMGN) intravenous medication teprotumumab (Tepezza) as the ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Tepezza (teprotumumab (Tepezza). This ...

It’s been 19 months since Amgen completed its $27.8 billion acquisition of Horizon Therapeutics, and the California company ...

In the weeks to come, the European Commission will issue a decision on the first severe thyroid eye disease treatment.

The European Medicines Agency (EMA) has recommended marketing authorization for Tepezza (teprotumumab) for adults with ...

Amgen on Thursday said its first-quarter profit rose 24%, driven by product sales, and said that while it is premature to ...

What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Busch sold 1,000 shares of Amgen. The total transaction amounted to $279,690. As of Wednesday ...

Thyroid eye disease (TED) therapy Tepezza – the biggest asset in Amgen's $26 billion takeover of Horizon last year – could soon face competition from a drug in the same class from Viridian ...

AMGN's 14 products, including Repatha, Blincyto, Tezspire, Tavneos and Evenity, achieve double-digit volume growth in the first quarter.

Amgen on Thursday said its first-quarter profit rose 24%, handily exceeding Wall Street expectations, as product sales ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Tepezza (teprotumumab (Tepezza). This ...